WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...
SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long ...
Source: Getty Images High-dose radiotherapy “needs the addition of short-term ADT to improve outcomes in intermediate- and high-risk localized prostate cancer,” according to Nicolas Demogeot, MD. The ...
NRG 0815 is a "landmark" study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer. Adding 6 months ...
Primary results from the Phase II ARASEC trial show that NUBEQA ® (darolutamide) plus androgen deprivation therapy (ADT) showed a statistically significant improvement in progression-free survival ...
Mehmet AN Şendur; Muhammed Bülent Akıncı; Nuriye Yıldırım Ozdemir; Sercan Aksoy; Didem S Dede; Arife Ulas; Nurullah Zengin; Bülent Yalçın In a recent reported randomized, Phase III E3805 trial, 790 ...
Androgen-deprivation therapy (ADT) has, for more than 70 years, been the mainstay of treatment for patients with metastatic prostate cancer. Now, results of a phase III clinical trial reveal that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results